A life science investment firm with offices in New York and San Francisco. The firm is currently making investments out of a new $250 million venture fund backed by strategic LPs, which closed in 2016. The firm typically makes investments ranging from $5-$20 million into selected companies, most commonly in the form of equity. The firm is open to companies globally.
The firm is looking to invest in the therapeutics space and is open to considering both small molecules and biologics. The firm is looking for companies in the clinical stage that are at least post proof-of-concept. The firm is generally open to all therapeutic subsectors and indications and is particularly interested in unmet needs.
The firm is looking for management teams with experience that are backed by strong science and a solid strategy. The firm looks to act as a hands-on investor, generally taking a board seat following investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email email@example.com